Freeline Therapeutics shares are trading higher after the company announced it was granted ILAP designation in the U.K. by MHRA for LFT201.
Portfolio Pulse from Benzinga Newsdesk
Freeline Therapeutics' shares are trading higher after the company received ILAP designation in the U.K. by MHRA for LFT201.
May 22, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Freeline Therapeutics shares are trading higher after receiving ILAP designation in the U.K. by MHRA for LFT201.
Freeline Therapeutics (FRLN) received ILAP designation for LFT201 by MHRA in the U.K., which is a positive development for the company. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100